MAP2K7 and thyroid cancer: A MEK inhibitor, selumetinib, enhanced the cytotoxic effects of lenvatinib [32], suggesting that thyroid cancer cells switch cell growth modalities from AKT-dependent to MEK/ERK-dependent mode to acquire resistance against lenvatinib.